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Practical use of blactchford score
Abstract
Aim: To retrospectively evaluate the use of proton pump inhibitor infusions.
Methods: A retrospective chart review was conducted of all patients who received an 80 mg bolus of
esomeprazole follow by an infusion at 8 mg/hr. An analysis was performed to determine if a Blatchford
Score of > 5 was a predictor of upper gastrointestinal ulcers.
Results: 300 patients received high dose esomeprazole over a 15 month period. 32% had an ulcer
identified on endoscopy. Gastritis and esophagitis were the second most common diagnosis accounting
for 16% of patients. A Blatchford Score of >5 as a predictor of upper gastrointestinal ulcers had a
sensitivity of 86.5% with a specificity of 32%.
Conclusion: Utilizing the Blatchford Score to predict patients that have an upper gastrointestinal ulcer
does not appear to be effective in clinical practice.
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Aim: To retrospectively evaluate the use of proton pump inhibitor infusions.
Methods: A retrospective chart review was conducted of all patients who received
an 80 mg bolus of esomeprazole follow by an infusion at 8 mg/hr. An analysis
was performed to determine if a Blatchford Score of > 5 was a predictor of upper
gastrointestinal ulcers.
Results: 300 patients received high dose esomeprazole over a 15 month period. 32%
had an ulcer identified on endoscopy. Gastritis and esophagitis were the second most
common diagnosis accounting for 16% of patients. A Blatchford Score of >5 as a
predictor of upper gastrointestinal ulcers had a sensitivity of 86.5% with a specificity
of 32%.
Conclusion: Utilizing the Blatchford Score to predict patients that have an upper
gastrointestinal ulcer does not appear to be effective in clinical practice.
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Introduction
The role of proton pump inhibitors (PPIs) for the prevention of
rebleeding in patients after therapeutic endoscopy for non-variceal
upper gastrointestinal tract bleeding (UGIB) is well established.
Acidic environments prevent platelet aggregation and coagulation
as well as cause clot lysis;1,2 therefore, raising the pH of gastric
contents creates an environment suitable for both clot formation
and stabilization. A sustained pH of 6 prevents clot lysis and allows
for platelets to aggregate. Both proton pump inhibitors (PPIs) and
histamine 2 receptor antagonists raise gastric pH, however, only PPIs
have the desired potency to achieve a sustained pH of 6.3,4
Initial studies evaluating PPIs for suspected UGIB failed to
illustrate clinical benefits.5 In these studies, endoscopy was not utilized
as a treatment modality; rather, it was used solely as a diagnostic tool.
Haemostasis with endoscopy is the treatment of choice for non-variceal
UGIB as it has shown to reduce bleeding and the need for surgery, as
well as decrease mortality.6,7 Later study initiating high dose PPIs as
a bolus and 72 hour infusion post-therapeutic endoscopy showed a
decrease in re-bleeding.8 Further studies showed that initiating a PPI
bolus and infusion prior to endoscopy resulted in decreasing oozing at
the site of the ulcer and a reduction in the need for endoscopic therapy
without affecting other clinical outcomes.9,10 The authors suggested
that high risk patients with suspected non-variceal UGIB may benefit
from high dose PPIs prior to endoscopy.
High risk patients with UGIB who may benefit from PPIs prior
to endoscopy is challenging. The Blatchford Score was created to
identify high risk patients who may require intervention.11,12 Although
a Blatchford Score of greater than zero has shown to good sensitivity
for determining high risk patients, it lacks the specificity to make it
useful in clinical practice.13,14 The objective of this study was determine
if patients are appropriately receiving PPIs for suspected UGIB in
the emergency department (ED) and to evaluate the sensitivity and
specificity of a Blatchford Score of >5 as a predictor of patient with
UGIB ulcers.
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Methods
This was a retrospective review of patients who received a PPI
bolus and infusion while in the ED at a busy community hospital
who receives >95,000 visits annually. Patients were identified
through a pharmacy medication records database. Information was
retrospectively collected over a 15 month period. To be included in
the study, patients must have received an 80mg bolus of esomeprazole
and been initiated on an esomeprazole drip at 8mg/hr while in the
ED. Esomeprazole was chosen as this was the formulary PPI agent
during the time of study. Patients were excluded from the study if care
was withdrawn or had advanced directives that precluded them from
receiving invasive procedures or dictated conservative care measures.
This study was approved by the institutional review board.
To be classified as appropriate, patients had to have an upper
gastrointestinal ulcer identified upon endoscopy during their inpatient
stay or in the ED. When an endoscopy did not identify an ulcer or
when a patient did not undergo endoscopy, they were classified as
inappropriate. Subsequently, these patients were categorized into
several categories based on the endoscopic findings or as not having
an endoscopy: variceal upper GI bleed, gastritis or esophagitis,
endoscopy not done, normal upper gastrointestinal tract, or other (i.e:
hiatal hernia, atriovenous malformation).
For each patient, all scoring components of the Blatchford Score
were collected (Table 1). At the conclusion of data collection, a
Blatchford Score was calculated for each patient. A 2x2 table was
constructed to determine the sensitivity and specificity of a Blatchford
Score of >5 as a predictor of the presence of an upper GI ulcer. The
definitive diagnosis of an ulcer was made through retrospective
review of patient’s charts and upper GI endoscopy reports. Patients
that did not undergo upper GI endoscopy were considered not to have
an ulcer present.
The primary objective of this study was to determine the number
of patients that received an esomeprazole bolus of 80 mg followed
by an infusion at 8mg/hr and had an upper GI ulcer identified upon
endoscopy. A secondary objective of this study was to determine the
sensitivity and specificity of a Blatchford Score of >5 for identifying
patients with an upper GI ulcer.
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did not undergo an upper GI endoscopy while present in the ED or
during their inpatient stay.

Table 1 Blatchford Score were collected
Risk marker
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Score component value

Blood urea nitrogen (mg/dL)
>18.2to <22.4

2

>22.4 to<28

3

>28 to< 70

4

>70

6

Hemoglobin men (g/dL)
>12 to <13

1

>10 to <12

3

<10

6

The median Blatchford Score calculated was 8 and ranged from 0
to 20 (Figure 2). A Blatchford Score of >5 correctly predicted an ulcer
in 84 patients (Table 2). The sensitivity of a Blatchford Score >5 for
predicting an ulcer in patients the received an esomeprazole bolus and
infusion while in the ED was 86.5% with a specificity of 32%.
Table 2 A Blatchford Score of >5 correctly predicted an ulcer in 84 patients
Endoscopic findings
Ulcer

No ulcer

Blatchford

>5

84 (TP*)

138 (FP*)

Score

<5

13 (FN*)

65 (TN*)

97

203

Total

*True Positive (TP); False Positive (FP); False Negative (FN); True Negative
(TN)

Hemoglobin women (g/dL)
>10to<12

1

<10

6

Systolic blood pressure (mmHg)
>100to<109

1

>90to99

2

<90

3

Other markers
Pulse Rate >100 Beats/Min

1

Presentation with Melena

1

Presentation with Syncope

2

Hepatic Disease

2

Heart Failure

2

Figure 1 300 patients an ulcer was found during an upper GI endoscopy in
96 (32%) patients.

Results
Over a 15 month period 313 patients were initiated on an 80mg
bolus of esomeprazole followed by an infusion at 8mg/hr. Of these
patients, 13 were excluded due to withdrawal of care or an advance
directive prohibited them from undergoing upper GI endoscopy. The
median time to endoscopy was 19.5 hours and ranged from 1 to 433.5
hours. In the remaining 300 patients an ulcer was found during an
upper GI endoscopy in 96 (32%) patients (Figure 1). Among the
patients that an ulcer identified, 31 (10.3%) required intervention such
as cauterization and/or epinephrine injections to stop bleeding. The
most common finding upper GI pathology found in patients that did
not have an ulcer was gastritis or esophagitis, followed by variceal
UGIB at (16%) and (12%) respectively. Sixteen percent of patients

Figure 2 The median Blatchford Score calculated was 8 and ranged from 0
to 20
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Discussion
A PPI bolus and infusion after therapeutic endoscopy reduces the
rate of re-bleeding among patients with upper GI ulcers. In high risk
patients, a bolus and infusion prior to endoscopy reduces the need for
endoscopic intervention and the signs of bleeding. Determining which
patients are at high risk is difficult. Only 32% of patients over a 15
month period received an esomeprazole bolus and infusion while in
the ED had an ulcer. Almost 30% of patients did not have any upper
GI pathology present or did not undergo endoscopy.
The administration of PPIs is not without risk. Chronic acid
suppression has been associated with life threatening electrolyte
abnormalities.15 Critically ill patients receiving acid suppression
for stress ulcer prophylaxis are at increased risk for respiratory
infections.16–18 Additionally, the use of PPIs has been associated
with the development of Clostridium difficile infections.19–21 Recent
studies have suggested that there is a dose response relationship with
administration of PPIs and that risk of Clostridium difficile infection
can develop in as soon as three days with PPI therapy.22,23 Inappropriate
administration of high dose PPIs in the ED could place patients at
an increased risk for the future development for Clostridium difficile
infections later in their hospital course.
Variceal upper GI bleeding was the second most common
diagnosis among patients reviewed. Potential treatment options
for patients with variceal bleeding include the use of somatostatin
analogues and band ligation.23 High dose PPIs in combination with
octreotide, a somatostatin analogue, in patients with variceal bleeding
has not shown benefit in regards to patient outcomes or transfusion
requirements.24 Providers often initiate PPI bolus and infusions
empirically in patients with presumed variceal bleeding despite the
lack of proven benefit. Of the patients in our study that were found
to have variceal bleeding, none had concomitant upper GI ulcers and
were therefore unlikely to have received additional benefit from the
use of high dose esomeprazole. In the future, exclusion of patients
with variceal bleeding may reduce the unnecessary use of high dose
PPIs.
This study identified that more objective criteria is needed to
identify patients at high risk for upper GI ulcers. The Blatchford Score
was developed to identify patients that required treatment to manage
their bleeding12,13 While this scoring system has been identified
by some practice guidelines as a tool for identifying patients that
may require intervention,25 its usefulness in clinical practice may
be limited.13,26,27 In our study we attempted to evaluate whether a
Blatchford Score of >5 would predict patients that would have an
ulcer identified upon endoscopy. Previous studies have shown that
scores of 5 or greater may an appropriate threshold for which patients
may require intervention.12,26 In our study, a sensitivity analysis
revealed that the Blatchford Score of >5 would identify most patients
with upper GI ulcers but had a specificity of only 32% which limits its
application in clinical practice.
Several limitations exist in this study. Patients were included
in this study were initiated on an esomeprazole bolus and infusion
while in the ED regardless of whether they were continued on the
infusion if they were admitted to the hospital. Therefore the duration
of the infusion was not taken into account when evaluating their
use, although this was unlikely to have influenced the incidence of
identifiable ulcers. In addition our study included all patients in the
ED that had received a bolus and infusion of esomeprazole over a
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15 month period which represented a relatively non-specific patient
population. More stringent exclusion criteria may provide better
results in future studies evaluating the utility of the Blatchford Score.
As the patients in our study were initiated on therapy in the ED, results
may differ for inpatients initiated on high dose PPIs.

Conclusion
The findings of our study illustrated that only 32% of patients in
the ED initiated on high dose esomeprazole had an ulcer identified
on endoscopy. A Blatchford Score of >5 may not be helpful in
determining high risk patients who may benefit from a PPI bolus
and infusion prior to endoscopy. Future study is needed to identify
objective criteria that can help detect patients that could benefit from
PPIs prior to endoscopy.
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